Samsara Free cash flow increased by 10.5% to $61.72M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 27.2%, from $48.51M to $61.72M. Over 4 years (FY 2022 to FY 2026), Free cash flow shows an upward trend with a 2.1% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | Q4 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$40.58M | -$47.61M | -$44.95M | -$57.71M | -$59.45M | -$43.24M | -$23.20M | -$10.38M | $7.96M | $4.72M | $8.53M | -$43.97M | $18.61M | $13.13M | $31.24M | $48.51M | $45.69M | $44.19M | $55.85M | $61.72M |
| QoQ Change | — | -17.3% | +5.6% | -28.4% | -3.0% | +27.3% | +46.4% | +55.3% | +176.7% | -40.7% | +81.0% | -615.3% | +142.3% | -29.5% | +138.0% | +55.3% | -5.8% | -3.3% | +26.4% | +10.5% |
| YoY Change | — | — | — | — | -46.5% | +9.2% | +48.4% | +82.0% | +113.4% | +110.9% | +136.8% | -323.8% | +133.9% | +178.3% | +266.0% | +210.3% | +145.6% | +236.7% | +78.8% | +27.2% |